Rheumatoid Arthritis News

DMARD interruptions in patients with autoimmune rheumatic diseases increased more than 80% between December 2020 and May 2021, leading to higher rates of self-reported flares, according to data published in Arthritis Care & Research.

Rheumatoid arthritis-related mortality rates are declining, but death rates related to rheumatoid arthritis-interstitial lung disease remain stable for adults younger than 65 years, researchers reported.

In an interview with Healio, Bonnie L. Bermas, MD, Dr. Morris Ziff Distinguished Professor in Rheumatology at UT Southwestern Medical Center, discussed some of the challenges women of reproductive age with RA face, special considerations when planning pregnancy in this patient population, the importance of coordinating care and more.

Virtual learning collaboratives, which are less intensive and relatively low-cost compared with in-person models, can improve treat-to-target implementation for rheumatoid arthritis, according to data published in Arthritis Care & Research.

Sinusitis, acute respiratory tract burden and even pharyngitis — also known as the common cold — are potential risk factors for rheumatoid arthritis, according to data published in The Journal of Rheumatology.

The FDA has approved the seventh biosimilar to adalimumab, adalimumab-aqvh, for all eligible indications of the biologic product, the latest in an increasingly crowded biosimilar logjam set to release in 2023.

It was 2013 when data from the Human Microbiome Project first demonstrated that the presence of Prevotella bacteria in the gut strongly correlated with disease in patients with new-onset untreated rheumatoid arthritis.

Research continues to suggest that vagus nerve stimulation may become an “exciting alternative” treatment for those with rheumatoid arthritis, according to Mark C. Genovese, MD.

Rheumatology patients and clinicians alike express a “strong” preference for in-person visits rather than telemedicine, citing concerns over reduced assessment accuracy and increased inequality for vulnerable groups, according to data from the U.K.

The use of hydroxychloroquine during pregnancy is not associated with structural birth defects or any other outcomes, save for birth head circumference, according to data published in Arthritis & Rheumatology.